Art***Pei

Healthcare system lead

学歴

Georgetown University

Georgetown University (2015 - 2017)

  • Degree: Master of Science - MS
  • Field of Study: Biotechnology
  • Description:

University of Science and Technology of China (2011 - 2015)

  • Degree: Bachelor of Science - BS
  • Field of Study: Life Science
  • Description:

スキル:

Strategy, Valuation, Business Development, Management Consulting

職務経験:

Healthcare system lead at Novartis

  • Location: Shanghai, China
  • Duration: 2023-04 to Present
  • Description:

Chief of Staff and Director of Corp Strategy at Fosun Kite | 复星凯特

  • Location:
  • Duration: 2022-06 to 2023-04
  • Description: Taking in charge of strategic works from corp level to commercial and portfolio. lead Yescarta and Tecartus new indication and new product planning Achived new round capital injections from shareholders Contribute to 52% QoQ sales growth and 163% YoY sales grwoth of Yescarta China sales Set 1/3/10 years company strategic planning and corp goals

Senior manager - BD and strategy at Overland Pharmaceuticals

  • Location: 中国 上海市
  • Duration: 2020-04 to 2022-06
  • Description: Strategic partnering, joint venture, and license deal with overseas biotech companies. Independently close 2 deals with 11 products; ADCT: build joint venture with ADC Therapeutics with license of Phase 3 CD19 ADC and other 3 ADCs ALLO: build joint venture with Allogene with license of 5 globally first-in-class allo CAR-T in both solid tumor and hem-onc Company strategy and portfolio strategy: New product planning; corp 5-year planning etc.

Strategic Planning Manager at Roche

  • Location: Shanghai
  • Duration: 2020-01 to 2020-04
  • Description: Took in charge of Roche oncology GI&GU franchise strategy and new product planning in China. Worked closely with Roche global Team to develop GI&GU oncology franchise strategy in China. Led a cross-functional team to build new product strategies including development strategy, portfolio prioritization, commercial assessment, business case, and revenue forecast, etc... Supported BU in marketed or pre-market product marketing strategies including pre-launch marketing, product pricing, market access, competitive intelligence, business case, and other market strategies.

Consulting Manager at Frost & Sullivan

  • Location: Shanghai City, China
  • Duration: 2017 to 2019-12
  • Description: Led a 5-people team and conducted strategy, market intelligence analysis, valuation, and commercial DD of innovative drug sector in management consulting, IPOs, M&A and equity investment projects. Led 6 strategy consulting projects regarding BD, in-license deal & investment strategy, market access strategy, pricing strategy for biotech companies and multinational pharmaceutical companies. Involved in the over 20 HK/NASDAQ/SH IPO events of biotech companies like BeiGene, Innovent, WuxiApptec, HanSoh, and others. Involved in 1 M&A deal and 3 equity investment deals of biotech companies. Help such companies raising USD5.3 Billion in total. Supported and 10+ in-licenses deals in commercial assessment, revenue forecast and financial analysis. Sophisticated in valuation and revenue forecasting modeling, especially for the risk-adjusted DCF valuation model in the field of biotech and pharma.
AI履歴書分析

候補者インテリジェンスレポート

米国の採用ディレクターの視点からAI分析 — キャリアの継続性、成長軌道、および役職適合性を評価します。

キャリアの継続性とリスク評価

Employment GapLow

No observable employment gaps; timeline shows continuous progression with no substantial breaks.

Industry ConsistencyLow

All roles are within healthcare/pharma/biotech strategy, partnerships, and market access, indicating strong industry alignment.

Tenure StabilityMedium

Several short stints (Roche 4 months, Fosun Kite ~10 months) raise moderate concerns about long-term role stability, though subsequent roles show upward trajectory and strategic scope.

Education-Career MatchLow

Georgetown University credential aligns with leadership in healthcare strategy; no evident mismatch between education and career path (degree field not specified).

キャリア成長カーブ

Consulting Manager Entry
Frost & Sullivan
2017 - 2019
Strategic Planning Manager Lateral
Roche
2020-01 to 2020-04
Senior Manager - BD and Strategy ↑ 昇進
Overland Pharmaceuticals
2020-04 to 2022-06
Chief of Staff and Director of Corp Strategy ↑ 昇進
Fosun Kite
2022-06 to 2023-04
Healthcare System Lead ↑ 昇進
Novartis
2023-04 to Present
評価:Arthur Pei demonstrates a consistent upward trajectory in pharma strategic leadership, with increasing scope from market intelligence and valuation to corporate strategy, BD, and country-level healthcare system leadership. The track record suggests readiness for senior VP or CSO-level roles with global responsibility, especially in oncology and gene therapy spaces.

最適な役職(トップ5)

1

Chief Strategy Officer (CSO) / VP Corporate Strategy, Global Pharma96% 適合

Proven leadership in corporate strategy, portfolio planning, and BD with successful Asia-Pacific and China market initiatives; strong track record with top-tier pharma groups.

2

Head of Corporate Development & Strategy – Oncology Franchise, Asia-Pacific92% 適合

Deep oncology product experience, successful JV/licensing deals, and APAC market focus align with global oncology strategy leadership.

3

Senior Director, Strategic Partnerships & BD, Global Biotech/Pharma89% 適合

Independent deal-making experience with multiple products and cross-border partnerships; strong due diligence and financial modeling background.

4

VP/Director of Strategy & Market Access, China83% 適合

Solid experience in market access, pricing, pre-launch marketing, and China market strategy, complementing global strategy leadership.

5

Head of Strategy & Commercial Excellence, Oncology80% 適合

Broad strategic leadership with oncology focus and portfolio planning; suitable for global head of commercial strategy roles in oncology.

AI Recruiterを体験する

無料で始めましょう。ライバルに先を越されないでください。

AI駆動の採用ソリューションを活用して、採用プロセスを自動化し、時間コストの80%を削減している10,000社以上の企業に加わりましょう。

33%オフ、残り48時間のみ!
AIを無料で試す

24時間365日自動運用

AIを活用した候補者スクリーニング

地理的・時差の制限なく採用活動

パーソナライズされたインテリジェントコミュニケーション

候補者エンゲージメントの自動評価

あなたの採用スタイルをインテリジェントに模倣・再現

4ヶ月間の返金保証

LinkedInアカウントのセキュリティを確保